No Data
BAIYUNSHAN PH (00874.HK) plans to hold a Board of Directors meeting on March 13 to approve the annual performance.
Glory Financial announced on February 28 that BAIYUNSHAN PH (00874.HK) has determined that the Board of Directors will hold a meeting on March 13, 2025 (Thursday) to review and approve the audited financial performance of the company and its subsidiaries for the twelve months ending December 31, 2024, and to address other matters (if any).
BAIYUNSHAN PH: Date of Board Meeting
BAIYUNSHAN PH (00874): Guangzhou Pharmaceutical sells the second additional Assets with a consideration of 0.583 billion yuan.
BAIYUNSHAN PH (00874) announced that on February 28, 2025, Guangzhou Pharmaceutical and Xingzheng Asset Management, based on the underlying assets...
BAIYUNSHAN PH (00874.HK) subsidiary sells accounts receivable.
On February 28, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that on February 28, 2025, Guangzhou Medicine (a non-wholly-owned subsidiary of the company) signed a "Newly Added Base Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the basic asset sale agreement (Phase IV), confirming the sale of the second batch of newly added base assets to Xingzheng Asset Management, and received a purchase payment of 0.583 billion yuan.
Express News | Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln
BAIYUNSHAN PH (600332.SH): Subsidiary recognized as a high-tech enterprise.
On February 19, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that four of its subsidiaries, including Guangzhou BAIYUNSHAN PH Guanghua Pharmaceutical Co., Ltd. and Guangyao Wanglaoji (Bijie) Industrial Co., Ltd., have passed the high-tech enterprise certification and received the "High-tech Enterprise Certificate" jointly issued by the provincial department of science and technology, the finance department, and the tax bureau where these companies are registered.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down